Eusol BiotechLtd Past Earnings Performance
Past criteria checks 0/6
Eusol BiotechLtd has been growing earnings at an average annual rate of 29.1%, while the Biotechs industry saw earnings growing at 17.8% annually.
Key information
29.1%
Earnings growth rate
31.0%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | n/a |
| Return on equity | -12.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Eusol BiotechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -52 | 17 | 25 |
| 30 Sep 23 | 0 | -26 | 17 | 29 |
| 30 Jun 23 | 0 | 0 | 17 | 34 |
| 31 Mar 23 | 0 | -9 | 21 | 43 |
| 31 Dec 22 | 0 | -18 | 24 | 52 |
| 30 Sep 22 | 0 | -61 | 26 | 68 |
| 30 Jun 22 | 0 | -103 | 28 | 83 |
| 31 Mar 22 | 0 | -113 | 27 | 90 |
| 31 Dec 21 | 0 | -123 | 25 | 98 |
| 30 Sep 21 | 0 | -117 | 24 | 93 |
| 30 Jun 21 | 0 | -111 | 24 | 89 |
| 31 Mar 21 | 0 | -113 | 23 | 91 |
| 31 Dec 20 | 0 | -114 | 22 | 93 |
| 30 Sep 20 | 0 | -115 | 22 | 94 |
| 30 Jun 20 | 0 | -117 | 22 | 96 |
| 31 Mar 20 | 0 | -112 | 23 | 93 |
| 31 Dec 19 | 0 | -107 | 25 | 89 |
| 30 Sep 19 | 0 | -123 | 26 | 104 |
| 30 Jun 19 | 0 | -139 | 28 | 118 |
| 31 Mar 19 | 0 | -167 | 29 | 156 |
| 31 Dec 18 | 0 | -194 | 29 | 194 |
| 30 Sep 18 | 0 | -222 | 30 | 221 |
| 30 Jun 18 | 1 | -249 | 30 | 248 |
| 31 Mar 18 | 1 | -233 | 31 | 219 |
| 31 Dec 17 | 1 | -217 | 32 | 189 |
| 30 Sep 17 | 0 | -171 | 28 | 146 |
| 30 Jun 17 | 0 | -125 | 24 | 104 |
| 31 Mar 17 | 0 | -112 | 21 | 91 |
| 31 Dec 16 | 0 | -99 | 18 | 78 |
| 31 Dec 15 | 0 | -87 | 18 | 65 |
Quality Earnings: 6652 is currently unprofitable.
Growing Profit Margin: 6652 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6652 is unprofitable, but has reduced losses over the past 5 years at a rate of 29.1% per year.
Accelerating Growth: Unable to compare 6652's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6652 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 6652 has a negative Return on Equity (-12.87%), as it is currently unprofitable.